What is HC Wainwright's Forecast for Korro Bio Q1 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Korro Bio in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($2.54) for the quarter, down from their prior forecast of ($2.45). HC Wainwright has a "Buy" rating and a $115.00 price target on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio's Q2 2025 earnings at ($2.67) EPS, Q3 2025 earnings at ($2.82) EPS, Q4 2025 earnings at ($2.97) EPS and FY2025 earnings at ($11.00) EPS.

Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, topping analysts' consensus estimates of ($2.33) by $0.07. The firm had revenue of $2.27 million for the quarter.

A number of other equities research analysts also recently weighed in on KRRO. Royal Bank of Canada lowered their target price on Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a report on Wednesday, March 19th. Oppenheimer initiated coverage on shares of Korro Bio in a research note on Friday, January 10th. They issued an "outperform" rating and a $155.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $142.57.

Korro Bio Stock Performance

Shares of KRRO stock traded up $0.62 during mid-day trading on Monday, hitting $18.38. The company's stock had a trading volume of 173,025 shares, compared to its average volume of 88,620. Korro Bio has a 52 week low of $16.77 and a 52 week high of $98.00. The company's fifty day simple moving average is $28.87 and its 200-day simple moving average is $40.93. The company has a market cap of $172.57 million, a PE ratio of -1.96 and a beta of 2.13.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in KRRO. Wellington Management Group LLP raised its holdings in shares of Korro Bio by 11.5% in the 4th quarter. Wellington Management Group LLP now owns 14,553 shares of the company's stock worth $554,000 after acquiring an additional 1,501 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Korro Bio by 997.3% in the fourth quarter. California State Teachers Retirement System now owns 4,850 shares of the company's stock worth $185,000 after purchasing an additional 4,408 shares during the last quarter. Woodline Partners LP bought a new position in shares of Korro Bio in the fourth quarter valued at approximately $3,887,000. Point72 Asset Management L.P. boosted its position in shares of Korro Bio by 11.0% during the fourth quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company's stock valued at $18,806,000 after buying an additional 49,147 shares during the last quarter. Finally, Polar Capital Holdings Plc bought a new stake in Korro Bio during the fourth quarter worth $2,855,000. 13.18% of the stock is owned by institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).